Aft Pharmaceuticals (ASX: AFP) — Perfil da empresa, notícias e dados financeiros
AFT Pharmaceuticals develops a broad portfolio of pharmaceutical products, including both proprietary and in-licensed drugs.

Aft Pharmaceuticals
Aft Pharmaceuticals is a New Zealand-based pharmaceutical company that develops, licenses, and commercializes proprietary and over-the-counter healthcare products globally. Founded in 1997, the company focuses on delivering therapeutic formulations across key categories including pain management, eyecare, dermatology, cold and flu, and prescription medicines. Its flagship patented pain relief formulation, Maxigesic, is distributed across multiple international markets. Aft Pharmaceuticals operates distribution networks across Australasia, Asia-Pacific, North America, Europe, and Africa, partnering with healthcare providers, retail pharmacies, and clinical networks to deliver prescription and non-prescription treatments.
Resumo
Operações
Produtos e/ou serviços de Aft Pharmaceuticals
- Patented Pain Management: Formulation and global distribution of patented dual-action pain relief products combining paracetamol and ibuprofen. Available in oral tablets, intravenous, liquid, and hot drink formats across international pharmaceutical markets in Australasia, Europe, the Americas, and Asia.
- Over-the-Counter Healthcare: Non-prescription consumer health products covering pain relief, allergy care, cold and flu remedies, and gastrointestinal treatments. Distributed through retail pharmacy channels, supermarkets, and online platforms across New Zealand, Australia, and select export markets.
- Prescription Pharmaceuticals: Development and marketing of branded and generic prescription medications across diverse therapeutic categories, including cardiovascular health, pain management, dermatology, oncology, and central nervous system disorders supplied directly to healthcare professionals and hospital pharmacy networks.
- Hospital and Critical Care Products: Specialized injectable pharmaceuticals, critical care medications, and hospital-grade therapies supplied to public health authorities and private clinical facilities across Australasian markets, supporting inpatient surgical, emergency, and specialized therapeutic treatment regimens.
- Ophthalmic and Eyecare Range: Specialized eye care treatments including preservative-free lubricating drops, dry eye therapies, and anti-inflammatory ophthalmic formulations distributed to eye clinics, optometrists, and retail pharmacies across regional and international distribution networks.
- Dermatology and Skincare Therapies: Topical dermatological treatments, antibacterial creams, and specialized skin care products designed for infection management and wound care, distributed through community pharmacies, medical practices, and healthcare distribution channels across global markets.
equipe executiva do Aft Pharmaceuticals
- Hartley AtkinsonCo-Founder, CEO, MD & Executive Director
- Marree AtkinsonCo-Founder, Chief of Staff & Executive Director
- Stuart D. HoulistonChief Financial Officer
- Ioana StanescuChief Scientific Officer
- Murray KeithGroup Marketing Manager
Últimas notícias sobre a Aft Pharmaceuticals
AFT Pharmaceuticals targets NZ$300M revenue following growth
AustraliaAFT Pharmaceuticals licenses pain treatment in Japan
AustraliaAFT Pharmaceuticals tracks towards NZ$300M target
AustraliaAFT Pharmaceuticals iron project targets US$7.41B
AustraliaAFT Pharmaceuticals reports record FY26 profit and growth
AustraliaAFT Pharmaceuticals names Stuart Houliston as CFO
Australia
Comunicados recentes
O que a Aft Pharmaceuticals (AFP) comunicou ao mercado, do mais recente para o mais antigo.
- AFT 1H27 financial results and conference call
- AFT reports double digit growth in 1H FY27 and R&D progress
- Application for quotation of securities - AFP
- Capital Change Notice
Histórico de dividendos
Dividendos por ação pagos pela Aft Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026 | — | NZ$0.0162 | — | NZ$0.0162 |
| FY2025 | — | NZ$0.0111 | — | NZ$0.0111 |
| FY2024 | — | NZ$0.0098 | — | NZ$0.0098 |
| FY2023 | — | NZ$0.0069 | — | NZ$0.0069 |
Principais indicadores financeiros
Resultados divulgados pela Aft Pharmaceuticals, em NZD.
- Cap. de mercado
- 373,4 mi
- Receita (TTM)
- 254,7 mi
- P/L
- 29.7
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- 0.7%
- Margem de lucro
- 5.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 256,6 mi | 25 mi | 14,8 mi | |
| 205,5 mi | 11,7 mi | 12 mi | |
| 194 mi | 20,3 mi | 15,6 mi | |
| 156,6 mi | 19,7 mi | 10,7 mi |